Veradermics, Inc.

Quick facts

Phase 3 pipeline

• VDPHL01 · Oncology
  VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme.
• VDPHL01 BID · Sleep disorders
  VDPHL01 BID is a small molecule that targets the H3 histamine receptor.
• VDPHL01 QD · Inflammatory diseases
  VDPHL01 QD is a small molecule that targets the H3 histone deacetylase (HDAC) to modulate gene expression.

Phase 2 pipeline

• VDMN-21 Patch High Dose
• VDMN-21 Patch Low Dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Veradermics, Inc. portfolio CI brief
• Veradermics, Inc. pipeline updates RSS